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Abstract
Background: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. While abdominal
pain is a dominant symptom of IBS, many sufferers also report widespread hypersensitivity and present with
other chronic pain conditions. The presence of widespread hypersensitivity and extra-intestinal pain conditions
suggests central nervous dysfunction. While central nervous system dysfunction may involve the spinal cord
(central sensitisation) and brain, this review will focus on one brain mechanism, descending pain modulation.
Method/design: We will conduct a comprehensive search for the articles indexed in the databases Ovid
MEDLINE, Ovid Embase, Ovid PsycINFO and Cochrane Central Register of Controlled Trial (CENTRAL) from their
inception to August 2015, that report on any aspect of descending pain modulation in irritable bowel syndrome.
Two independent reviewers will screen studies for eligibility, assess risk of bias and extract relevant data. Results
will be tabulated and, if possible, a meta-analysis will be carried out.
Discussion: The systematic review outlined in this protocol aims to summarise current knowledge regarding
descending pain modulation in IBS.
Systematic review registration: PROSPERO CRD42015024284
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Background
Irritable bowel syndrome (IBS) is a chronic gastrointes-
tinal disorder characterised by abdominal pain, discom-
fort and altered bowel habit [1].
A significant amount of research suggests that the
abdominal pain associated with IBS is due to peripheral
changes occurring in the gut (visceral nociceptive hyper-
sensitivity) [2–4]. However, not all people with IBS have
evidence of visceral hypersensitivity, and some exhibit
nociceptive hypersensitivity in non-visceral structures
(e.g. cutaneous structures) [5, 6]. Such non-visceral
hypersensitivity may even be widespread extending to
regions quite distant from the site of concern. In addition,
other non-visceral, extra-intestinal chronic pain condi-
tions frequently occur with IBS such as fibromyalgia,
chronic low back pain, chronic fatigue, dysmenorrhea and
cystitis (bacterial and interstitial cystitis) [7].
While peripheral mechanisms remain important in
IBS, when widespread hypersensitivity and extra-
intestinal pain syndromes occur, this suggests a central
nervous system involvement [8–11]. Central nervous
system nociceptive processing is commonly divided
into spinal cord processes (central sensitisation) and
those occurring in the brain (e.g. descending pain
modulation) [12].
The term descending pain modulation (DPM) is used
to describe the process mediated by pathways descend-
ing from the brain stem that modulate spinal cord as-
cending nociceptive transmission. Descending neural
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modulatory circuits from the brain are able to inhibit or
facilitate ascending nociceptive transmission and are also
known to be influenced by cognitive processes and
mood. Ultimately, changes in DPM are felt to pro-
foundly influence pain perception.
We will undertake a systematic review of the re-
search examining descending pain modulation in IBS.
As part of this review, we will examine the influence
of cognitive processes and mood on descending modu-
lation [13].
This systematic review will summarise current know-
ledge and identify unresolved questions regarding de-
scending pain modulation in IBS.
Research questions
This systematic review aims to answer the following
research questions: (1) Do people with IBS when
compared with healthy controls demonstrate a con-
sistent difference in descending pain modulation as
assessed by neurophysiological testing (change in pain
intensity and waveform analysis) and (2) If descending
pain modulation is altered in people with IBS com-




The protocol of this systematic review has been regis-
tered on PROSPERO 2015 [14] (registration number:
CRD42015024284). The protocol has been conducted
and reported using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment guidelines [15].
Search strategy for identification of relevant studies
To identify the relevant literature, electronic searches
will be conducted in the following databases: Ovid
MEDLINE, Ovid Embase, Ovid PsycINFO and
Cochrane Central Register of Controlled Trial (CEN-
TRAL) from their inception to August 2015. A com-
prehensive search strategy has been designed with the
assistance of an experienced research librarian and
adjusted to account for differences in indexing across
databases. Articles identified through reference lists of
included studies and relevant systematic reviews will
be considered for inclusion based on their title. In
addition, cross-checking of references, citations in
review papers, and communication with scientists who
have been working in the field will also be carried out.
Non-English language studies will be included, where
a translation can be made available. See Appendix for
the MEDLINE search strategy.
Eligibility criteria
Participants
We will include studies of adults (18 years or older) who
have been diagnosed with IBS where the diagnosis has
been made according to the ROME criteria [16].
Studies of adults with comorbid intestinal disorders
(e.g. gastroesophageal reflux dysphagia, esophageal
spasms and functional dyspepsia) and/or extra-intestinal
disorders (e.g. low back pain, fibromyalgia, chronic fa-
tigue, dysmenorrhea and both bacterial and interstitial
cystitis) alongside IBS will also be included.
Outcome measure
The outcome of interest is descending pain modulation
function in people with IBS as assessed by neurophysio-
logical testing i.e. conditioned pain modulation (CPM)
or offset analgesia (OA). The neurophysiological proto-
col has to use a painful test stimulus assessed both prior
to and during and/or after the presentation of a condi-
tioning stimulus. Descending pain modulation in the
control group would be expected to be quantified as
normally responsive. Those studies where descending
pain modulation in control participants are not quanti-
fied as normally responsive, will be examined as a poten-
tial source of variability and will be considered as a
candidate for a stratified meta-analysis.
Types of studies
The study designs considered relevant to this review
include cross-sectional studies, case-control studies,
cohort studies and randomised controlled trials. Qualita-
tive studies will be excluded. We will exclude interven-
tion studies if assessment of descending pain modulation
is only reported after treatment (e.g. drug administra-
tion, surgical techniques). Reference lists of relevant
systematic reviews will be checked in order to identify
relevant primary studies, but systematic reviews will
otherwise be excluded.
Screening of studies
Following the initial database search, duplicate papers
will be removed and two reviewers will independently
screen titles and abstracts of selected studies to identify
those, which are potentially suitable and meet the inclu-
sion criteria.
These studies will then be reviewed in full text by two
reviewers to determine their eligibility using a standar-
dised eligibility criteria sheet. Reasons for exclusion of
papers will be recorded when screening full papers. Any
discrepancies in this final list will be discussed between
the reviewers, with an independent reviewer consulted if
a consensus cannot be attained.
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Data extraction
Data from the included studies will be extracted using a
standardised eligibility criteria sheet. Any discrepancies
in this final list will be discussed between the reviewers,
with an independent reviewer consulted if a consensus
cannot be attained. In addition, authors of papers will be
contacted where there is incomplete data or data that
needs further clarification.
The following data will be collected from the included
studies. General study information: authors, year of pub-
lication, sample size, language; study design: cross-
sectional, case-control, observational study or clinical
trial; clinical setting: primary care, specialist clinic, hos-
pital outpatient department; participant characteristics:
age, gender, classification or diagnostic criteria used,
duration of pain, severity of pain; measure of descending
pain modulation: conditioning stimulus, test stimulus,
outcome measure and time points outcome measure
were recorded; measure of cognitive processes and
mood: assessment type used.
Risk of bias assessment
Several risks of bias tools including the non-
randomised studies of interventions (ACROBAT-NRSI)
[17] and the quality assessment tool for diagnostic
accuracy studies-2 (QUADAS-2) [18] were evaluated
according to the guidelines outlined in the Cochrane
handbook for systematic reviews. The domains of bias
listed in these tools were developed for randomised or
non-randomised clinical trials and were not suitable for
the current review.
The Quality in Prognostic Studies (QUIPS) tool
developed by Hayden, van der Windt, Cartwright,
Cote´, Bombardier [19] was also considered for risk
of bias assessment. The QUIPS tool is comprised of
six important domains of bias and includes prompt-
ing items to help inform the judgement of risk of
bias. Each bias domain is then individually rated as
having a high, moderate or low risk of bias. How-
ever, not all items were considered relevant to this
review. For example, while attrition is important in
longitudinal studies, the studies central to the
current review are cross-sectional in nature. In the
event that longitudinal studies are included, only
baseline responses will be evaluated. The QUIPS tool
was considered the closest in design to that required
for this review. However, the use of a graded risk of
bias assessment within domains and an overall quan-
titative risk score was considered problematic. It was
felt that ranking risk criteria within each category as
low, medium or high introduced further subjectivity
to the assessment.
With these limitations taken together, a modified ver-
sion of the QUIPS risk of bias tool was employed. The
risk of bias tool developed for the current review con-
sists of six categories including: (1) The criteria out-
line by the ROME foundation [16] to assess whether
cases are representative of population, (2) comparabil-
ity of cases and controls, (3) participants clearly de-
fined, (4) quality of CPM protocol, (5) blinding and
(6) statistical methods and study size. As used in the
Cochrane risk of bias tool for non-randomised studies
of interventions (ACROBAT-NRSI) [17], each study
will be rating as having met (yes) or not met (no)
each bias domain according to the guidelines outlined
in the tool (see Table 1). In studies where there is un-
certainty in a category, the category will be rated as
“unclear”. A summary of the results for all included
studies will be provided and a qualitative analysis will
be undertaken. Inter-rater agreement of the risk of
bias tool will be tested by calculating a kappa statis-
tic. Any disagreements will be discussed between the
reviewers, with an independent reviewer consulted if
consensus cannot be attained.
Data analysis
Results for descending pain modulation function
within a study will be tabulated according to the
type of measure used for assessment (e.g. change in
pain intensity rating or neurophysiological measure).
The effect size for descending pain modulation func-
tion within a study will then be calculated using
means and standard deviations at baseline (prior to
testing) and during or following testing in the pa-
tient and control populations. When a variety of
effect size measures are reported, they will be con-
verted to a common measure when that is possible,
such as to Cohen’s d [20] or correlation values [21].
For each measure available, the random effects
model of DerSimonian and Laird [22] will be used
to create pooled effect sizes which will be reported
along with 95 % confidence intervals. When there is
no or little between-study variability, the random-
effects model is mathematically equivalent to the
fixed-effects model. Initially, all studies reporting
each measure will be included. Homogeneity of ef-
fect sizes will be assessed via inspection of forest
plots and via Cochrane’s test [22] and reported with
I2 values [23] to quantify the degree of between-
study variability. The potential for publication bias
will be assessed through inspection of funnel plots
and via Egger’s test [24]. Where substantial or
statistically significant between-study variability is
detected and the candidate sources of such variabil-
ity can be identified, stratified meta-analyses will be
conducted.
In addition, if there are adequate data in the included
studies, a separate analysis will also be carried out to
Chakiath et al. Systematic Reviews  (2015) 4:175 Page 3 of 6
investigate the influence that cognitive processes (e.g.
hypervigilance, catastrophising and self-efficacy) and
mood (e.g. depression and anxiety) have on neuro-
physiological measures of descending modulation.
Lastly, if the heterogeneity of the data does not allow
pooling and quantitative statistics, a narrative synthesis
of the findings will be undertaken and the implications
critically discussed.
Table 1 Risk of bias tool
Author and year of publication
Study identifier
Reviewer
Bias domain Issues to consider for judging overall rating of “risk of bias” Rating
Yes/no/
unclear
1. Cases representative of population
Diagnosis of IBS Diagnosis of IBS made according to the ROME criteria
2. Comparability of cases and controls
Inclusion/exclusion criteria for healthy controls
specified
Ensure controls also use ROME criteria
Ensure controls are comparable to cases in terms of
age and gender
3. Participants clearly defined
All clinical and demographical characteristics described • Clinical and demographical characteristics were fully described (yes/
no)
• Sample size (yes/no)
• Mean age (yes/no)
• Gender percentages (yes/no)
• Mean pain duration (yes/no)
• Mean pain intensity (yes/no)
Clinical setting Clinical setting clearly specified
4. Quality of conditioned pain modulation
(CPM) protocol
Testing explicitly described • Testing protocol (CPM) explicitly described (yes/no)
• Number of examiners preforming assessments (yes/no)
• Equipment used (yes/no)
• Clear description of procedure including number of assessments
and sites (yes/no)
5. Blinding
Assessor blinding Assessors were blinded to participant group or condition
6. Statistical methods and study size
Method of determining study size described and
appropriate
Method of determining study design was explicitly
described and appropriate
Confounding variables controlled Were confounding variables controlled? (e.g. through exclusion
criteria, matched controls, statistical analysis)
• Medication (yes/no)
• Caffeine (yes/no)
• Day of testing (yes/no)
• Pain on test day (yes/no)
• Time of day testing was undertaken (yes/no)
• Menstrual cycle phase (yes/no)
• Other pain or sensory conditions (yes/no)
Presentation of analytical strategy Statistical analysis explicitly described
and appropriate
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Discussion
This systematic review will consolidate our current
knowledge of descending pain modulation in IBS.
Appendix
Ovid MEDLINE search strategy
1. irritable Bowel Syndrome/
2. (visceral adj pain).mp. [mp = title, abstract, original
title, name of substance word, subject heading word,
keyword heading word, protocol supplementary
concept word, rare disease supplementary concept
word, unique identifier]


























29. quantitative sensory test*.mp.
30. QST.mp.
31. detection threshold.mp.
32. ((cold or warm) adj detection).mp.
33. electrophysiologic*.mp
34. experim* adj pain.mp.
35. pain adj measurement.mp.
36. pain adj test.mp.
37. temporal summation.mp.
38. pain adj threshold.mp.
39. wind up.mp.
40. pain adj tolerance.mp.
41. (pain adj processing).mp.
42. spinal reflex*.mp.
43. reflex receptive field or RRF.mp.
44. nociceptive withdrawal reflex.mp.
45. nociceptive flexion reflex.mp.
46. NFR.mp.
47. NWR.mp.
48. (RIII adj reflex).mp.
49. conditioned pain modulation or CPM.mp.
50. cold pressor test.mp.
51. diffuse noxious inhibitory control/
52. DNIC.mp.
53. offset adj analgesia.mp.
54. neural inhibition.mp.
55. descending pain modulation.mp.
56. endogenous pain modulation.mp.
57. central pain modulation.mp.
58. or/6–57
59. 5 and 58
60. qualitative research/
61. 59 not 60
62. limit 61 to humans
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